ArticleUnited European gastroenterology journal2019
A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent
Article in United European gastroenterology journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06156956 (Fecal Microbiota Transplantation to Eradicate Antibiotic-resistance Bacteria From the Gastrointestinal Tract of Patients at High Risk of Infection and/or to Cut Off the Spread of Bacteria With Dangerous Mechanisms of Antibiotic Resistance), which is not on this map. Cited by 33 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fecal Microbiota Transplantation to Eradicate Antibiotic-resistance Bacteria From the Gastrointestinal Tract of Patients at High Risk of Infection and/or to Cut Off the Spread of Bacteria With Dangerous Mechanisms of Antibiotic Resistance
Who cites it
33 citing papers in PubMed, 5 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Comparative effectiveness of treatments for recurrentFrontiers in pharmacology · 2024Pooled it
- Clinical trials targeting the gut-microbiome to effect ocular health: a systematic review.Eye (London, England) · 2023Pooled it
- Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).The Cochrane database of systematic reviews · 2023Pooled it
- Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile.Digestive diseases and sciences · 2022Pooled it
- Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials.Frontiers in cellular and infection microbiology · 2022Pooled it
- Cross-kingdom microbial associations characterize responsiveness to fecal microbiota transplantation in patients with irritable bowel syndrome.Journal of translational medicine · 2026Article
- The effects of filtration and centrifugation on the gut microbiota in fecal microbiota transplantation preparation.Frontiers in microbiology · 2026Article
- Comparative effectiveness of different therapies forThe Lancet regional health. Europe · 2025Article
- Management of Recurrent Clostridioides difficile Infection (rCDI): A Systematic Literature Review to Assess the Feasibility of Indirect Treatment Comparison (ITC).Infectious diseases and therapy · 2025Review
- Microbiota and enteric nervous system crosstalk in diabetic gastroenteropathy: bridging mechanistic insights to microbiome-based therapies.Frontiers in cellular and infection microbiology · 2025Review
- Therapeutics involved in managing initial and recurrentWorld journal of gastrointestinal pharmacology and therapeutics · 2024Review
- Validation of Lyophilized Human Fecal Microbiota for the Treatment ofMicroorganisms · 2024Article
- Review
- Assessment of fecal bacterial viability and diversity in fresh and frozen fecal microbiota transplant (FMT) product in horses.BMC veterinary research · 2024Article
- Comparative Efficacy of Fecal Microbiota Transplantation in Treating Refractory or RecurrentBiomedicines · 2024Article
- Microbiota-Based Therapeutics as New Standard-of-Care Treatment for RecurrentVisceral medicine · 2024Review
- Controversies in the Prevention and Treatment ofMicroorganisms · 2023Review
- The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review.Frontiers in microbiology · 2023Review
- Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection.Digestive diseases and sciences · 2022Review
- The Regulatory Approach for Faecal Microbiota Transplantation as Treatment forAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrence remains a challenge in Objective: In this NWM we assessed the comparative effectiveness of various therapies for rCDI to examine the efficacy rank order and determine the optimum therapeutic approach. Methods: A Bayesian network meta-analysis was performed to investigate the efficacy rank order of rCDI interventions. Results: Six eligible RCTs were entered into an NWM. They included 348 rCDI patients, in whom seven therapeutic interventions were used, i.e. donor fecal microbiota transplantation (DFMT), vancomycin, fidaxomicin, vancomycin + DFMT, vancomycin + bowel lavage, autologous FMT and placebo. DFMT showed the highest efficacy in comparison with vancomycin [odds ratio (95% credible interval), 20.02 (7.05-70.03)] and fidaxomicin (22.01 (4.38-109.63)). Conclusion: This NWM showed that DFMT is the optimum therapeutic approach for rCDI, as it was the most efficacious among various therapeutic interventions, particularly in comparison with commonly used antibiotics such as vancomycin or fidaxomicin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.